OClawVPS.com
Moderna
Edit

Moderna

https://www.modernatx.com/
Last activity: 08.04.2026
Active
Categories: BioTechHealthcaremRNAPharmaceuticalsVaccines
At Moderna, we believe messenger RNA, or mRNA, is the “software of life.” Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease.

Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients.

We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured.

This Moderna page is not the appropriate place to report adverse events (side-effects ) for any products. If you are or someone you know is experiencing a side effects, please reach out to your healthcare professional. Moderna is continuously monitoring the safety of its products. We encourage you to report any side effects directly to us at 1‑866‑MODERNA (1‑866‑663‑3762).
Likes
21.97K
Followers
514.92K
Website visits
385.4K /mo.
Mentions
500
Location: United States
Employees: 1001-5000
Phone: (617) 621-2936
Total raised: $1.7B
Founded date: 2010

Investors 3

Funding Rounds 5

DateSeriesAmountInvestors
07.12.2018IPO$600M-
01.02.2018Series G$500M-
06.01.2015-$450M-
24.11.2013-$110M-
06.12.2012-$40M-

Mentions in press and media 500

DateTitleDescription
08.04.2026We’re exiting our position in a drug stock and initiating a stake in a more attractive rival-
07.04.2026HexemBio Raises $10.4M in Seed FundingHexemBio, a NYC-based biotechnology company developing blood stem cell rejuvenation therapies, raised $10.4M in Seed funding. The round was led by Draper Associates with participation from SOSV, Seraphim, and other investors. The company in...
13.03.2026From a start-up biotech firm to a global vaccine giant-
06.03.2026FDA vaccine head will step down in April after string of controversial decisionsVinay Prasad is leaving his post as director of the Center for Biologics Evaluation and Research. The top vaccine and biologics drug official in the U.S. Food and Drug Administration will step down in April. The agency made multiple decisio...
06.03.2026FDA reversals leave investors worrying about the fates of other experimental drugsThe FDA in the past year has denied or discouraged applications of at least eight new drugs, according to RTW Investments. The agency initially refused to review Moderna’s flu shot before reversing course. Companies have accused the FDA of ...
04.03.2026Stocks making the biggest moves premarket: Moderna, Ross Stores, Box, Gitlab and more-
04.03.2026Stocks making the biggest moves midday: Coinbase, CoreWeave, KKR, Moderna, Brown-Forman & more-
28.02.2026ИИ-лаборатория LUMI открыла усилитель мРНК-терапии — без человеческих гипотез и подсказокИсследователи из Университета Торонто создали LUMI-lab — автономную лабораторию, которая объединяет ИИ-модель, активное обучение и робототехнику. За десять итеративных циклов система самостоятельно синтезировала и протестировала более 1700 ...
27.02.2026There’s a ‘bearish-to-bullish’ reversal happening in this mid-cap biotech stock, says Carter Worth-
26.02.2026Dynavox Group bolsters management team to support effective growth and scalingDynavox Group bolsters management team to support effective growth and scaling Thu, Feb 26, 2026 09:00 CET Report this content Dynavox Group, the world leader in assistive communication, today announced that it has appointed two new members...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In